Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Observational × Efficacy, Team × Nivolumab × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 13 Melanoma 11 Head and Neck Neoplasms 5 Squamous Cell Carcinoma of Head and Neck 4 Neoplasms 4 Lung Neoplasms 3 Stomach Neoplasms 2 Neoplasm Metastasis 2 Gastrointestinal Neoplasms 2 Esophageal Squamous Cell Carcinoma 2 Carcinoma, Hepatocellular 2 Thyroid Neoplasms 1 Skin Neoplasms 1 Sexual Dysfunction, Physiological 1 Recurrent Squamous Cell Lung Carcinoma 1 Recurrence 1 Oropharyngeal Neoplasms 1 Neoplasms, Squamous Cell 1 Motor Activity 1 Lung Squamous Cell Carcinoma Stage IV 1 Locally Advanced Melanoma 1 Locally Advanced Gastric Cancer 1 Liver Diseases 1 Kidney Neoplasms 1 Hereditary Sensory and Autonomic Neuropathies 1 Eunuchism 1 Esophageal Neoplasms 1 Erectile Dysfunction 1 Efficacy, Team 1 Dysplastic Nevus Syndrome 1

Interventions

pembrolizumab 1 Nivolumab 1 Immune Checkpoint Inhibitors 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06693440 2024-11-18

The Immune Assessment of PD-1 Antibody Therapy in Tumor

Henan Cancer Hospital

Efficacy, Team

Data powered by HemOnc (CC BY 4.0) Colophon ⚡